Evidence map›Paper›PMID 33680086›Full record

ArticleEcancermedicalscience2021

The effect of the COVID-19 pandemic on paediatric cancer care: lessons learnt from a major paediatric oncology department in Turkey.

Mustafa Tezer Kutluk, Fahad Ahmed, Meral Kirazlı, İnci Yaman Bajin, Eren Müngen, Saniye Ekinci, Ferah Yıldız

Abstract read
In one paragraph

Article in Ecancermedicalscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology?Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mustafa Tezer KutlukDepartment of Pediatric Oncology, Hacettepe University Faculty of Medicine & Cancer Institute, 06100 Ankara, Turkey.
Fahad AhmedDepartment of Pediatric Oncology, Hacettepe University Faculty of Medicine & Cancer Institute, 06100 Ankara, Turkey.
Meral KirazlıDepartment of Pediatric Oncology, Hacettepe University Faculty of Medicine & Cancer Institute, 06100 Ankara, Turkey.
İnci Yaman BajinDepartment of Pediatric Oncology, Hacettepe University Faculty of Medicine & Cancer Institute, 06100 Ankara, Turkey.
Eren MüngenDepartment of Pediatric Oncology, Hacettepe University Faculty of Medicine & Cancer Institute, 06100 Ankara, Turkey.
Saniye EkinciDepartment of Pediatric Surgery, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey.
Ferah YıldızDepartment of Radiation Oncology, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has disrupted cancer care. An audit at a major Paediatric Oncology Department in Turkey was performed to determine its impact on paediatric cancer care. A comparison was made among the number of daily paediatric cancer patients, diagnostic and treatment procedures. The data for the 'COVID-19 period' (10 March to 31 October 2020) were compared with the corresponding 'prior year control period' (10 March to 31 October 2019). Moreover, presentation delay (duration between first symptoms to healthcare visit) was calculated for new cases. The findings indicate that the mean 34.7 outpatients per day during 'COVID-19 period' was significantly lower than the 'prior year control period' (52.2). There were 17.7 inpatients per day during the 'COVID-19 period' which was significantly lower than 23.8 inpatients per day during the 'prior year control period'. Significant reduction in the daily mean number of patients undergoing chemotherapy, radiotherapy, surgery and imaging studies during the 'COVID-19 period' was also evident. A negative trend in the diagnosis of new paediatric cancers was evident with 128 new cancer cases during the 'COVID-19 period', whereas the corresponding number was 212 for the 'prior year control period'. The presentation delay (median 31 days) remain unchanged during the 'COVID-19 period'. The findings suggest significant damage to paediatric cancer care during the COVID-19 pandemic. Appropriate obligatory actions by oncology societies and policymakers can minimise longer term negative impacts.

Indexed as

chemotherapyCOVID-19 pandemicdelayed diagnosispediatric cancerradiotherapysurgical procedures

Identifiers

PMID33680086
PMCPMC7929778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.